PfizerPFE
Codzienny briefing rynkowy
Ten briefing nie jest jeszcze dostępny w tym języku — wyświetlana jest wersja angielska.
Najnowszy briefing
Pfizer's Q2 2026 dividend of $0.43 per share declared, payable June 12, 2026.
Pfizer's Board of Directors declared a quarterly cash dividend of $0.43 per share for Q2 2026, payable on June 12, 2026, to shareholders of record as of May 8, 2026. This marks the 350th consecutive quarterly dividend paid by the company.
Poprzednie briefingi
Pfizer's stock price remains steady at $25.01 amid market stability.
Over the past 24 hours, there have been no significant developments affecting Pfizer's stock performance. The stock closed at $25.01 on July 31, 2026, with minimal intraday fluctuations. Investors are awaiting upcoming earnings reports and potential regulatory updates for future guidance.
Pfizer's Q2 2026 Dividend Declared at $0.43 per Share
Pfizer's Board of Directors has declared a quarterly cash dividend of $0.43 per share for the second quarter of 2026, payable on June 13, 2025, to shareholders of record as of May 9, 2025. This marks the 346th consecutive quarterly dividend paid by the company.
No significant market-moving news for Pfizer (PFE) in the past 24 hours.
Over the past 24 hours, there have been no significant developments affecting Pfizer's stock performance. The company continues to focus on its strategic initiatives, including cost-saving programs and acquisitions in oncology and obesity treatments. Investors are advised to monitor upcoming earnings reports and industry trends for potential impacts on Pfizer's stock.
Pfizer's stock rises 2.43% to $25.25 amid positive analyst outlook.
Pfizer's stock price increased by 2.43% to $25.25, following positive analyst assessments. RBC Capital upgraded Pfizer's rating to 'Sector Perform' with a $25.00 price target, citing improved valuation and upcoming catalysts. Additionally, the Swiss National Bank increased its stake in Pfizer by 7.1%, now holding approximately 16.7 million shares valued at $468.5 million.
Pfizer's stock remains stable at $24.67 amid Gabelli Funds' reduced stake.
In the past 24 hours, there have been no significant developments affecting Pfizer's stock performance. The stock closed at $24.67 on July 27, 2026, with an intraday high of $24.875 and a low of $24.45. Gabelli Funds LLC recently reduced its position in Pfizer by 11.8%, selling 67,900 shares and retaining 508,600 shares valued at approximately $14.3 million.
Pfizer's stock drops 1.9% to $24.53 amid cautious analyst outlook
Pfizer's stock declined by 1.9% to $24.53, influenced by cautious analyst perspectives and recent company developments.
Pfizer's stock remains stable amid strategic shift and AI healthcare focus.
Pfizer is navigating a post-pandemic landscape by refocusing on its core pharmaceutical portfolio, including oncology, vaccines, and internal medicine. The company is also exploring opportunities in AI healthcare to enhance diagnostics and treatment decisions. Despite these strategic shifts, there have been no significant market-moving developments in the past 24 hours.
Pfizer's stock drops 1.88% to $24.54 amid unusual options trading volume.
In the past 24 hours, Pfizer's stock declined by 1.88% to $24.54, accompanied by unusually high options trading volume. This suggests increased investor activity, potentially indicating market uncertainty or speculative interest.
Pfizer's stock remains stable at $25.01 amid recent developments.
In the past 24 hours, Pfizer's stock price has remained relatively unchanged at $25.01. Recent developments include a significant increase in call option activity and a notable sale of shares by PNC Financial Services Group Inc. However, no major news has emerged to significantly impact the stock's performance.
Pfizer's stock declines 0.42% amid new patent lawsuits over COVID-19 vaccine technology.
Pfizer's stock experienced a slight decline of 0.42% following the announcement of new international patent lawsuits filed by Arbutus Biopharma and Genevant Sciences. These lawsuits target Pfizer/BioNTech's use of mRNA lipid nanoparticle technology in their COVID-19 vaccine, seeking injunctions and monetary damages across Canada and much of the European Union. This legal action extends existing U.S. patent disputes into multiple major markets, potentially impacting Pfizer's mRNA franchise.
Pfizer's stock remains steady at $24.94 amid mixed market signals.
Over the past 24 hours, Pfizer's stock price has remained relatively unchanged, closing at $24.94 on July 21, 2026. This stability comes despite recent developments, including a 1.3% increase in share price on July 16, 2026, following FDA approval for a new bladder cancer regimen. However, the stock has also faced challenges, such as a 2.7% decline on June 24, 2026, due to a Phase 3 lung cancer drug candidate failing to meet survival expectations.
Pfizer's stock declines 1.2% amid cautious analyst sentiment and CFO departure
Pfizer's stock experienced a 1.2% decline, closing at $24.75 on July 20, 2026. This downturn is attributed to cautious analyst sentiment, with several firms recently lowering price targets, and the announcement of CFO Dave Denton's departure, effective August 15. Despite reaffirming its 2026 revenue guidance of $59.5 billion to $62.5 billion, the stock's consensus rating remains 'Hold' with an average target price of $28.50.
Pfizer's stock remains below key moving averages amid ongoing challenges.
Pfizer's stock continues to trade below its 50-day and 200-day simple moving averages, reflecting investor caution regarding the company's growth prospects. The stock closed at $25.05 on July 17, 2026, with an intraday high of $25.64 and a low of $24.975. Analysts have expressed concerns over declining COVID-related revenues and patent expirations, which may impact future earnings. Additionally, HSBC downgraded Pfizer's rating to 'Hold' due to a lack of near-term catalysts.
Pfizer's stock price declines amid patent loss concerns and analyst downgrades.
Pfizer's stock has experienced a decline due to concerns over upcoming patent expirations and recent analyst downgrades. Barclays initiated coverage with an underweight rating, citing challenges from patent losses and balance sheet constraints. Additionally, Guggenheim reduced its price target to $35, maintaining a Buy rating, following a model update.
Pfizer's stock drops 3% after CFO's surprise departure, despite guidance
Pfizer's stock declined by 3% following the unexpected announcement of CFO Dave Denton's resignation, effective August 15, 2026. Despite this, the company reaffirmed its 2026 financial outlook, maintaining revenue expectations of $59.5 billion to $62.5 billion and adjusted earnings per share between $2.80 and $3.00.
Pfizer's stock rises 1.3% to $25.13 amid FDA approval and analyst updates.
Pfizer's stock price increased by 1.3% to $25.13 following the FDA's approval of a new bladder cancer treatment regimen and positive analyst assessments. The company also declared a quarterly dividend of $0.43 per share, yielding approximately 6.9%.
Pfizer's stock rises 2.1% to $24.77 after FDA approves new bladder cancer treatment.
Pfizer's stock increased by 2.1% to $24.77 following the FDA's approval of PADCEV combined with Keytruda for treating muscle-invasive bladder cancer. This approval is expected to expand treatment options and patient reach. Despite this positive development, investor sentiment remains mixed due to concerns over patent expirations and pipeline challenges.
Pfizer's stock drops 2.4% amid analyst downgrades and cost-cutting plans
Pfizer's stock declined by 2.4% following recent analyst downgrades and the announcement of a cost-cutting initiative. HSBC downgraded the stock to "Hold," citing a lack of near-term catalysts, while Guggenheim reduced its price target to $35. Additionally, Pfizer initiated a multi-year cost reduction plan targeting $1.5 billion in savings by 2027.
Pfizer's stock price rises 1.2% amid analyst target cuts and FDA approval
Pfizer's stock experienced a 1.2% increase, closing at $24.46 on July 13, 2026. This uptick occurred despite recent analyst target reductions and the FDA's approval of PADCEV plus Keytruda for muscle-invasive bladder cancer.
Pfizer's stock remains near 52-week low at $24.25, offering 7.1% dividend yield.
Pfizer's stock price has stabilized around $24.25, close to its 52-week low, providing investors with a 7.1% dividend yield. This stability comes amid strategic shifts, including the $43 billion Seagen oncology acquisition aimed at doubling cancer revenue by 2030. However, the company faces challenges such as the loss of exclusivity for its top-selling drug, Eliquis, in Europe, which could impact future revenue.
HSBC downgrades Pfizer (PFE) to 'Hold' with $28 target amid pipeline concerns.
HSBC has downgraded Pfizer's stock rating to 'Hold' from 'Buy' and reduced the price target to $28, citing diminished confidence in the company's short-term growth prospects. This decision follows a 40% probability adjustment for the market introduction of sigvotatug vedotin after a Phase 3 trial failure in non-small cell lung cancer. Additionally, HSBC increased the beta coefficient to 0.85 from 0.78, indicating higher expected volatility.
Pfizer's stock price declines amid market gains; analysts express caution.
Pfizer's stock closed at $23.72 on July 6, 2026, a 2.47% decrease from the previous day, underperforming the S&P 500's 0.72% gain. Analysts have expressed caution due to the absence of near-term catalysts and potential challenges in the company's pipeline.
Pfizer's stock price remains steady at $24.25 amid cautious analyst outlook.
In the past 24 hours, there have been no significant developments affecting Pfizer's stock. The stock continues to trade at $24.25, reflecting a cautious market sentiment. Analysts maintain a 'Hold' rating, awaiting further catalysts to drive growth.
Pfizer's stock declines 2.6% amid CFO transition and pipeline challenges
Pfizer's stock experienced a 2.6% decline on July 8, 2026, closing at $25.26. This downturn is attributed to the announcement of CFO Dave Denton's departure and concerns over the company's product pipeline, particularly the impact of upcoming patent expirations.
Pfizer's stock rises 1.3% to $24.35 amid FDA approval for new breast cancer indication.
Pfizer's stock increased by 1.3% to $24.35 on July 7, 2026, following FDA approval of IBRANCE for a new breast cancer indication. Despite this positive development, the stock remains below its 50-day and 200-day moving averages, indicating potential investor caution.
Pfizer's stock drops 2.47% to $23.72 amid CFO departure and reaffirmed 2026 guidance.
Pfizer's stock declined by 2.47% to $23.72 following the announcement of CFO Dave Denton's unexpected departure, effective August 15, 2026. Despite this, the company reaffirmed its 2026 financial guidance, projecting revenues between $59.5 billion and $62.5 billion and adjusted diluted EPS between $2.80 and $3.00.
HSBC downgrades Pfizer to 'Hold' with $28 price target due to pipeline concerns
HSBC has downgraded Pfizer's stock rating from 'Buy' to 'Hold' and reduced its price target to $28, citing a lack of near-term catalysts and reduced confidence in the company's pipeline, particularly following a Phase 3 setback in non-small cell lung cancer. The revised price target suggests approximately 17% upside from the current stock price of $24.32.
Analizuj dowolny wykres w kilka sekund
To dzisiejsza ocena Pfizer. Skieruj aparat na dowolny wykres, a ChartDetector AI w kilka sekund dostarczy pełną analizę techniczną — za darmo na iOS.
Wygenerowane przez AI na podstawie publicznych źródeł wiadomości. To nie jest porada finansowa.